J Carl Barrett
Overview
Explore the profile of J Carl Barrett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
215
Citations
14745
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hollis R, Churchman M, Grimes G, Meynert A, Gautier P, McMahon L, et al.
Eur J Cancer
. 2025 Feb;
219:115299.
PMID: 39955805
Background: Half of high grade serous tubo-ovarian carcinomas (HGSOC) demonstrate homologous recombination repair (HRR) deficiency, most commonly through germline or somatic pathogenic variants in BRCA1/2 (gBRCA1/2 or sBRCA1/2). gBRCA1/2 is...
2.
Monette A, Warren S, Barrett J, Garnett-Benson C, Schalper K, Taube J, et al.
J Immunother Cancer
. 2024 Jul;
12(7).
PMID: 39032943
Therapies targeting the programmed cell death protein-1/programmed death-ligand 1 (PD-L1) (abbreviated as PD-(L)1) axis are a significant advancement in the treatment of many tumor types. However, many patients receiving these...
3.
Li Q, Cristini V, Gupta A, Achour I, Barrett J, Koay E
JCO Clin Cancer Inform
. 2024 Jul;
8:e2300254.
PMID: 38996196
Purpose: Early prediction of response to immunotherapy may help guide patient management by identifying resistance to treatment and allowing adaptation of therapies. This analysis evaluated a mathematical model of response...
4.
Xie M, Vuko M, Rodriguez-Canales J, Zimmermann J, Schick M, OBrien C, et al.
Mol Cancer
. 2024 May;
23(1):115.
PMID: 38811992
Background: We explored potential predictive biomarkers of immunotherapy response in patients with extensive-stage small-cell lung cancer (ES-SCLC) treated with durvalumab (D) + tremelimumab (T) + etoposide-platinum (EP), D + EP,...
5.
Kapil A, Spitzmuller A, Brieu N, Haneder S, Shumilov A, Meier A, et al.
Sci Rep
. 2024 May;
14(1):12129.
PMID: 38802399
Many targeted cancer therapies rely on biomarkers assessed by scoring of immunohistochemically (IHC)-stained tissue, which is subjective, semiquantitative, and does not account for expression heterogeneity. We describe an image analysis-based...
6.
Stetson D, Labrousse P, Russell H, Shera D, Abbosh C, Dougherty B, et al.
J Clin Oncol
. 2024 May;
42(23):2736-2740.
PMID: 38754043
No abstract available.
7.
Hardaker E, Sanseviero E, Karmokar A, Taylor D, Milo M, Michaloglou C, et al.
Nat Commun
. 2024 Feb;
15(1):1700.
PMID: 38402224
The Ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib in combination with the PD-L1 antibody durvalumab demonstrated encouraging clinical benefit in melanoma and lung cancer patients who progressed on immunotherapy. Here...
8.
Besse B, Pons-Tostivint E, Park K, Hartl S, Forde P, Hochmair M, et al.
Nat Med
. 2024 Feb;
30(3):716-729.
PMID: 38351187
For patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable molecular alterations, standard-of-care treatment is immunotherapy with anti-PD-(L)1 checkpoint inhibitors, alone or with platinum-doublet therapy. However, not all patients...
9.
Memon D, Schoenfeld A, Ye D, Fromm G, Rizvi H, Zhang X, et al.
Cancer Cell
. 2024 Jan;
42(2):209-224.e9.
PMID: 38215748
Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired...
10.
Johnson M, Serra Traynor C, Vishwanathan K, Overend P, Hartmaier R, Markovets A, et al.
Clin Pharmacol Ther
. 2023 Nov;
115(2):349-360.
PMID: 38010260
This exploratory, post hoc analysis aimed to model circulating tumor DNA (ctDNA) dynamics and predict disease progression in patients with treatment-naïve locally advanced/metastatic epidermal growth factor receptor mutation (EGFRm)-positive non-small...